Mastocytosis Treatment Market Size, Share, Industry, and Outlook (2026-2033)

Market Overview

The Global mastocytosis treatment market is expected to reach at a high CAGR during the forecast period 2026-2033.

Mastocytosis is a genetic immune disorder, in which certain immune cells, called mast cells, build up under the skin and in the bones, intestines and other organs. This abnormal growth of mast cells causes a range of symptoms, including itchy bumps on the skin, gastrointestinal (GI) issues such as diarrhea, and bone pain. It can increase the risk of anaphylaxis (a severe allergic response) when patients come across certain environmental triggers. In some cases, the mastocytosis can be aggressive and lead to death if left untreated. Mastocytosis is not contagious.

There are two types of mastocytosis, cutaneous and systemic types. Basically, there is no cure for mastocytosis, but treatment can help to manage and minimize the symptoms. Antihistamines, leukotriene modifiers, mast cell stabilizers and corticosteroid creams can relieve the symptoms of an allergic reaction, such as itchy skin lesions. In case of anaphylactic shock, an epinephrine injection is commonly used. Chemotherapy such as cladribine is used to treat aggressive systemic mastocytosis. Some patients with aggressive systemic mastocytosis may undergo an allogeneic hematopoietic stem cell transplant (also called a bone marrow transplant).

Market Scope

To Know More Insights - Download Sample

Market Dynamics

Increasing adoption of novel therapeutics

The increasing adoption of novel therapeutics is expected to drive the market over the forecast period. As there is no cure for mastocytosis, the treatment helps to minimize the symptoms. The development and adoption of novel therapeutics aim to address the unmet medical needs associated with the management of mastocytosis by providing more advanced approved therapeutics for better patient outcomes.

Blueprint Medicines Corporation cleared the U.S. Food and Drug Administration (FDA) acceptance of the company's supplemental new drug application for AYVAKIT (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM).

Moreover, many clinical trials are going on for the development of novel therapeutics that show better results in the management of mastocytosis. The regulatory approvals increase the trust in patients about the development and adoption of novel therapeutics.

Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, released the Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM). HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frameshifting and already has an Orphan Drug Designation from the FDA.

In addition, ongoing research and development efforts lead to the discovery of new therapeutics and the development of innovative drugs. As the understanding of mastocytosis at the molecular and cellular levels improves, novel therapeutics with targeted mechanisms of action may be identified and developed.

Further, the increasing prevalence of mastocytosis, rising FDA approvals, increasing clinical trials, increasing awareness about mastocytosis and available treatments and advancements in developing novel drugs and advanced therapies are expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the various drugs used in the mastocytosis treatment, adverse effects associated with the topical corticosteroids,  the high cost of the treatment of mastocytosis, availability of limited approved treatments and lack of appropriate treatment are expected to hamper the market. 

Market Segment Analysis

The global mastocytosis treatment market is segmented based on disease type, treatment type, sales channel and region.

The mast-cell stabilizers segment accounted for approximately 45.2% of the mastocytosis treatment market share

The mast-cell stabilizers segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for mastocytosis, but various types of drugs, therapies and various treatment options are used to minimize the symptoms of mastocytosis. The mast cell stabilizers are the most commonly used for the treatment of mastocytosis. The mast cell stabilizers such as cromolyn sodium and ketotifen are most commonly used. 

Ritedose, a pharmaceutical manufacturer, launched a new single-unit dose generic product, Cromolyn Sodium Oral Solution, 100 mg/5 ml. The oral solution is the first of a new product line for Ritedose Pharmaceuticals which has historically offered a portfolio of generic inhalation solutions. Cromolyn Sodium is a mast cell stabilizer, primarily used to treat the symptoms of mastocytosis.

Moreover, in mastocytosis, the mast cells are overly sensitive and can release excessive amounts of mediators like histamine, prostaglandins, and leukotrienes. Mast cell stabilizers, such as cromolyn sodium and nedocromil, work by stabilizing the membranes of mast cells, preventing them from releasing these inflammatory substances.

Further, mast cell activation leads to various symptoms, including itching, flushing, abdominal pain, and in severe cases, anaphylaxis. By inhibiting the release of mast cell mediators, mast cell stabilizers help reduce the intensity and frequency of these symptoms, improving the overall quality of life for individuals with mastocytosis and their wide adoption also increases the demand for mast cell stabilizers. 

Market Geographical Share

North America accounted for approximately 39.1% of the market share 

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is well-known for its strong presence of major players such as pharmaceutical companies and medical device companies developing mastocytosis treatment products. The presence of major players actively perform in clinical trials and research activities to develop novel and advanced therapeutics for the treatment of mastocytosis.

Furthermore, the region is also known for the presence of advanced healthcare infrastructure such as hospitals, specialty clinics, research and academic centers and others, which provides advanced healthcare facilities for patients in the treatment of mastocytosis by using advanced therapies for better patient outcomes. The region’s advanced healthcare facilities help to early prevention of the condition with minimal risks.

Key Developments

• May 2026: Cogent Biosciences continued advancing bezuclastinib for non-advanced systemic mastocytosis following FDA acceptance of its NDA supported by pivotal SUMMIT trial data. The therapy demonstrated durable symptom reduction, improved mast cell burden markers, and favorable long-term tolerability, strengthening next-generation KIT inhibitor development in mastocytosis treatment.
• March 2026: U.S. Food and Drug Administration accepted the NDA for bezuclastinib for non-advanced systemic mastocytosis, marking a major regulatory milestone for targeted KIT D816V inhibition therapy. The application was backed by statistically significant SUMMIT trial outcomes showing improvements in symptom severity, serum tryptase reduction, and disease control.
• January 2026: Cogent Biosciences reported additional long-term SUMMIT trial findings highlighting durable efficacy and safety of bezuclastinib in systemic mastocytosis patients. The company emphasized technological progress in selective KIT inhibition with reduced central nervous system penetration, aiming to improve chronic treatment tolerability.

Market Companies

The major global players in the mastocytosis treatment market include Novartis AG, Mylan N.V., Apotex Inc., Blueprint Medicines Corporation, CStone Pharmaceuticals, Viatris Inc., Cigna HealthCare, Ralington Pharma, Enzo Life Sciences, Inc., Genentech USA, Inc. and among others. 

Why Purchase the Report?

• To visualize the global mastocytosis treatment market segmentation based on disease type, treatment type, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of mastocytosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global mastocytosis treatment market report would provide approximately 61 tables, 63 figures, and 186 Pages.

Target Audience 

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies